checkAd

     237  0 Kommentare Pharmaceutical Advancements in Medicinal Marijuana Continue to Evolve While Producing Higher Quality Cannabinoid Extracts

    PALM BEACH, Florida, June 22, 2017 /PRNewswire/ --

    Latest research and development in the medicinal cannabis market is helping industry leaders identify breakthroughs and significant discoveries for developing new patents and therapies for various applications targeting diseases including forms of cancer and rare conditions. Cannabis companies in the markets this week with developments include: Puration, Inc. (OTC: PURA), GW Pharmaceuticals plc (NASDAQ: GWPH), CV Sciences Inc. (OTC: CVSI), 22nd Century Group Inc. (NASDAQ: XXII) and PotNetwork Holding Inc. (OTC: POTN)

    Puration, Inc. (OTC: PURA) today announced the Company has entered into a letter of intent agreement to acquire First Choice Nursery which has an existing twenty-five greenhouse facility. The company has the opportunity to expand to an additional 400 irrigated greenhouse pads ready for buildout. Puration has a U.S. Patented Cannabis Extraction process licensed from NCM Biotech. The license of the process to Puration is the first and only license NCM Biotech has executed. R&D with NCM Biotech's patented process has demonstrated a high potential for bringing FDA approved pharmaceutical products to market for the treatment of multiple neurological disorders and cancer. NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University and John McMichael, Ph.D., President and CEO Beech Tree Labs. 

    Puration's NCM Biotech Extractions Compared to GW Pharmaceutical (GWPH) - "I have received doctor feedback from more than one of our research initiatives that extracts coming from NCM Biotech's patented process are superior in purity and quality to any other available cannabis extracts," said Frederick Ferri, CEO and Founder of NCM Biotech. "Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical products and candidate products." Read this and more news for Puration at http://www.marketnewsupdates.com/news/pura.html.

    Lesen Sie auch

    Seite 1 von 4


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Pharmaceutical Advancements in Medicinal Marijuana Continue to Evolve While Producing Higher Quality Cannabinoid Extracts PALM BEACH, Florida, June 22, 2017 /PRNewswire/ - Latest research and development in the medicinal cannabis market is helping industry leaders identify breakthroughs and significant discoveries for developing new patents and therapies for various …